RUA vs. POLX, IHC, AVO, SUN, MHC, BELL, DEMG, NIOX, SN, and MXCT
Should you be buying RUA Life Sciences stock or one of its competitors? The main competitors of RUA Life Sciences include Polarean Imaging (POLX), Inspiration Healthcare Group (IHC), Advanced Oncotherapy (AVO), Surgical Innovations Group (SUN), MyHealthChecked (MHC), Belluscura (BELL), Deltex Medical Group (DEMG), NIOX Group (NIOX), Smith & Nephew (SN), and MaxCyte (MXCT). These companies are all part of the "medical devices" industry.
RUA Life Sciences vs. Its Competitors
RUA Life Sciences (LON:RUA) and Polarean Imaging (LON:POLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, community ranking, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.
In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Polarean Imaging'saverage media sentiment score.
RUA Life Sciences has a net margin of -65.72% compared to Polarean Imaging's net margin of -1,333.97%. RUA Life Sciences' return on equity of -26.38% beat Polarean Imaging's return on equity.
RUA Life Sciences has higher earnings, but lower revenue than Polarean Imaging. RUA Life Sciences is trading at a lower price-to-earnings ratio than Polarean Imaging, indicating that it is currently the more affordable of the two stocks.
Polarean Imaging received 23 more outperform votes than RUA Life Sciences when rated by MarketBeat users. Likewise, 67.65% of users gave Polarean Imaging an outperform vote while only 0.00% of users gave RUA Life Sciences an outperform vote.
26.0% of RUA Life Sciences shares are owned by institutional investors. Comparatively, 12.1% of Polarean Imaging shares are owned by institutional investors. 51.3% of RUA Life Sciences shares are owned by company insiders. Comparatively, 39.3% of Polarean Imaging shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
RUA Life Sciences has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, Polarean Imaging has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500.
Summary
RUA Life Sciences beats Polarean Imaging on 7 of the 13 factors compared between the two stocks.
Get RUA Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for RUA and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RUA Life Sciences Competitors List
Related Companies and Tools
This page (LON:RUA) was last updated on 6/13/2025 by MarketBeat.com Staff
